FI or Stage II colon cancer, in which the majority of patients are cured by surgical resection, the role of adjuvantchemotherapy is uncertain. Some subgroups of StageII patients are recognized to be at high risk for recurrence and may be potential candidates for adjuvant therapy.High-risk ...
5. Network, N.C.C., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer Version 2.2021. 2021. 6. Network, N.C.C., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Rect...
[5] Verschoor YL, et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study. 2022 ASCO abstr 3511. [6] Martinelli E, et al. Cetuximab Re...
504 Background: Microsatellite instability (MSI) testing has become critically important in clinical cancer care of patients with cancer given the recent pan-tumor FDA approval of pembrolizumab for use in patients with MSI-High (MSI-H) t... K Gowen,TA Clark,JP Gregg,... - 《Journal of Cl...
Professor Caprioli emphasized that all hard-to-treat colon sites were responsive, with transmural remissions occurring as barrier thickness gradually improved. Professor Milan Lukas from Charles University, Czech Republic, followed with a seminar titled "Infliximab CT-P13 SC in Clinical Trials and Real ...
However, as some previous work did not distinguish between dMMR and MSI for colorectal cancers, we also carried out a meta-analysis of prevalence estimates for colorectal, colon, or rectal cancer based on studies that combined results for dMMR and MSI. These analyses were carried out on three...
Tanios S. Bekaii-Saab, MD:This was part of the study, but we individualized it to the level of the patient. This was a patient with Lynch syndrome, who had gone through colon cancer and uterine cancer, and then pancreas cancer. In fact, had it resected and then came back and was tr...
5. Network, N.C.C., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Colon Cancer Version 2.2021. 2021. 6. Network, N.C.C., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Rectal Cancer Version 1.2021. 2021. ...
NCCN Guideline. Colon Cancer, 2020, Version 4 [DB/OL]. https://www.nccn.org. [7] SHAIKH T, HANDORF E A, MEYER J E, et al. Mismatch repair deficiency testing in patients with colorectal cancer and nonadherence...
The importance of reporting MSI status in colorectal cancer is based on its potential for guiding treatment and as a prognostic indicator. It is also used to identify patients for Lynch syndrome testing. Our aim was to evaluate pre-analytical factors, such as age of formalin-fixed and paraffin...